PubMed:21533811
Annnotations
Allie
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| SS1_21533811_2_0 | 258-298 | expanded | denotes | chemotherapy-induced nausea and vomiting |
| SS2_21533811_2_0 | 300-304 | abbr | denotes | CINV |
| SS1_21533811_2_1 | 382-412 | expanded | denotes | highly emetogenic chemotherapy |
| SS2_21533811_2_1 | 414-417 | abbr | denotes | HEC |
| SS1_21533811_2_2 | 445-465 | expanded | denotes | emergency department |
| SS2_21533811_2_2 | 467-469 | abbr | denotes | ED |
| SS1_21533811_4_0 | 565-578 | expanded | denotes | breast cancer |
| SS2_21533811_4_0 | 580-582 | abbr | denotes | BC |
| SS1_21533811_4_1 | 659-670 | expanded | denotes | lung cancer |
| SS2_21533811_4_1 | 672-674 | abbr | denotes | LC |
| AE1_21533811_2_0 | SS1_21533811_2_0 | SS2_21533811_2_0 | abbreviatedTo | chemotherapy-induced nausea and vomiting,CINV |
| AE1_21533811_2_1 | SS1_21533811_2_1 | SS2_21533811_2_1 | abbreviatedTo | highly emetogenic chemotherapy,HEC |
| AE1_21533811_2_2 | SS1_21533811_2_2 | SS2_21533811_2_2 | abbreviatedTo | emergency department,ED |
| AE1_21533811_4_0 | SS1_21533811_4_0 | SS2_21533811_4_0 | abbreviatedTo | breast cancer,BC |
| AE1_21533811_4_1 | SS1_21533811_4_1 | SS2_21533811_4_1 | abbreviatedTo | lung cancer,LC |
PubMed_Structured_Abstracts
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 209-482 | OBJECTIVE | denotes | The aim of this study was to compare the risk of chemotherapy-induced nausea and vomiting (CINV) events for various 5-HT(3) RAs in patients who received moderately (MEC) or highly emetogenic chemotherapy (HEC) by evaluating hospital or emergency department (ED) admissions. |
| T2 | 492-1154 | METHODS | denotes | PharMetrics claims database was used to identify patients diagnosed with breast cancer (BC) who were initiated on cyclophosphamide-based adjuvant chemotherapy or with lung cancer (LC) initiated on carboplatin-based or cisplatin-based chemotherapy between 2005 and 2008. Patients were stratified in two groups: those initiated and maintained on palonosetron versus those treated with any other 5-HT(3) RA regimens in the 6-month post first chemotherapy. Risk for CINV events, identified by ICD-9-CM for nausea, vomiting, and/or dehydration, were estimated using logistic regressions, controlling for age, gender, comorbidity, and total chemotherapy doses or days. |
| T3 | 1164-1891 | RESULTS | denotes | Of the 4,868 cyclophosphamide-treated BC, 5,414 carboplatin-treated LC, and 1,692 cisplatin-treated LC identified, there were 1,864 BC (38.5%), 1,806 carboplatin-treated LC (33.4%), and 390 cisplatin-treated LC (23.0%) in the palonosetron-only group. Palonosetron-only group had significantly lower probability of CINV events associated with ED/hospital admissions in all three cohorts (3.5% vs. 6.3% in BC, 9.5% vs. 13.8% in carboplatin-treated LC, and 16.4% vs. 22.6% in cisplatin-treated LC, all at p < 0.05). Logistic regressions found palonosetron-only group had significantly lower risk of CINV events (odds ratios = 0.550, 0.653, and 0.689 in BC, carboplatin-treated LC and cisplatin-treated LC, respectively, p < 0.05). |
| T4 | 1904-2139 | CONCLUSIONS | denotes | Patients with lung or breast cancer receiving MEC or HEC had significantly lower risk of CINV events associated with hospital/ED admissions if initiated and maintained on palonosetron relative to patients receiving 5-HT(3) RA regimens. |
PubmedHPO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 279-285 | HP_0002018 | denotes | nausea |
| T2 | 290-298 | HP_0002013 | denotes | vomiting |